Blood
Articles in this Issue
Tryptophan metabolism plays a significant role in multiple myeloma survival
Abstract Introduction Multiple myeloma (MM) is a hematological malignancy caused by abnormally proliferating plasma cell...
Real-world outcomes in T-cell/histiocyte-rich large B-cell lymphoma: Insights from the largest u.S. cohort to date
Abstract Background: T cell/histiocyte-rich large B cell lymphoma (THRLBCL) is a rare and aggressive subtype of diffuse large B cell lymphoma...
Long-term outcomes of double-negative T cell therapy in AML patients with relapse post allo-HSCT
Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the principal curative approaches in the treatment of acut...
AML blasts and monocytic myeloid-derived suppressor cells (M-MDSC) inhibit human mucosal-associated invariant t (MAIT) cells activation.
Abstract Introduction: In acute myeloid leukemia, tumor cells can evade and suppress the host immune system, contributing to tumor progressi...
National trends and disparities in chronic myeloid leukemia mortality in the United States from 1999–2020: A population-based analysis
Abstract Background: Chronic myeloid leukemia (CML) accounts for 15% of adult leukemias in the United States (U.S.). The introduction of tyr...
A genomic analysis of patients with chronic lymphocytic leukemia treated with fixed duration therapy in a first-line setting in alberta, Canada
Abstract Introduction: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Canada. Current Canadian guidelines recommend...
Predictive biomarkers of luspatercept and erythropoiesis-stimulating agent (ESA) hematological response and overall survival (OS) in patients with lower-risk myelodysplastic syndromes (LR-MDS) in the commands trial
Abstract Background: MDS are characterized by ineffective hematopoiesis, cytopenias, and clonal expansion, often progres...
A modified Delphi consensus on the management of patients with relapsed or refractory FLT3-mutated acute myeloid leukemia in four Latin American countries
Abstract Introduction: In Latin America (LATAM), there is variability in the management of specific patient (pt) groups with acute myeloid l...
EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress
Abstract Background and Significance: FL represents approximately 20%–30% of all non-Hodgkin lymphoma cases. The current standard of care (S...
Interim analysis of a placebo controlled study of dronabinol for adults with sickle cell disease and chronic pain
Abstract Introduction: Chronic pain is the greatest contributor to poor quality of life in people living with sickle cel...
Haploidentical hematopoietic stem cell transplantation in adults with severe sickle cell disease: Long-term outcomes using a modified conditioning regimen with peripheral blood stem cells.
Abstract Haploidentical Hematopoietic stem cell transplantation (haplo-HSCT) remains the only curative option for adults with advanced sickl...
CART–ASCT–CART2 sandwich regimen as frontline therapy: A phase II trial in patients with primary plasma cell leukemia
Abstract Background: Primary plasma cell leukemia (pPCL) is the most aggressive form of plasma cell malignancy with poor...
Utilization rate and outcomes of advance care planning in hematologic malignancies: A study using the trinetx research network
Abstract Background: Advance care planning (ACP) helps align patients' medical treatment with their values and preferenc...
Natural killer cell heterogeneity reflects AML cell-states and predicts clinical outcome at diagnosis
Abstract Background: Natural killer (NK) cells are innate lymphocytes with the unique ability to eliminate transformed or infected cells wit...
The time toxicity of CAR-T cell therapy for non-Hodgkin's lymphoma
Abstract Introduction: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape for many types of non-Hod...
Clostridium difficile infection in sickle cell disease: Trends, predictors, and complications in hospitalized patients
Abstract Background: Patients with sickle cell disease (SCD) often experience recurrent hospitalizations due to both acute complications and...
Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage
Abstract Background Acute leukaemias of ambiguous lineage (ALAL) is a rare and highly heterogeneous acute leukemia. Adult patients with ALAL...
Analysis of clinical and laboratory characteristics of ALL with atypical BCR::ABL1 fusion genes
Abstract Background: The BCR-ABL1 fusion gene, a hallmark of chronic myeloid leukemia (CML), is also present in several types of acute leuke...
Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells
Abstract Introduction: Second-line (2L) anti-CD19 CAR T-cell therapy (CART) with axicabtagene ciloleucel (axi) or lisocabtagene maraleucel (...
Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy
Abstract CD45-directed CAR-T cells (CART45) are a promising immunotherapy for a broad range of hematologic malignancies, given the pan-leuko...
Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease mice
Abstract Background – Direct HbS polymerization inhibitors bind to the surface of Hemoglobin S and block polymerization by disrupting key su...
Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage
Abstract Acute leukemias of ambiguous lineage (ALAL) are characterized by ≥ 20% abnormal progenitors without clear differentiation along a s...
Dasatinib as 2nd line treatment is safe and effective in peruvian CML patients: A multicentric real-world study
Abstract Background: The second-generation tyrosine kinase inhibitor Dasatinib (DAS) used as second-line treatment is a valid option in pati...
Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group
Abstract Background The treatment landscape of acute myeloid leukemia (AML) is rapidly evolving due to advances in novel targeted agents, lo...
Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis
Abstract Introduction Treatment-free remission (TFR) has become a new and important goal of therapy for patients (pts) with chronic myeloid...